These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 22520542)

  • 1. Relationship of antihypertensive treatment to plasma markers of vascular inflammation and remodeling in the Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis study.
    Zamani P; Ganz P; Libby P; Sutradhar SC; Rifai N; Nicholls SJ; Nissen SE; Kinlay S
    Am Heart J; 2012 Apr; 163(4):735-40. PubMed ID: 22520542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial.
    Nissen SE; Tuzcu EM; Libby P; Thompson PD; Ghali M; Garza D; Berman L; Shi H; Buebendorf E; Topol EJ;
    JAMA; 2004 Nov; 292(18):2217-25. PubMed ID: 15536108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antihypertensive therapy and regression of coronary artery disease: insights from the Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis (CAMELOT) and Norvasc for Regression of Manifest Atherosclerotic Lesions by Intravascular Sonographic Evaluation (NORMALISE) trials.
    Brener SJ; Ivanc TB; Poliszczuk R; Chen M; Tuzcu EM; Hu T; Frid DJ; Nissen SE
    Am Heart J; 2006 Dec; 152(6):1059-63. PubMed ID: 17161053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of inter-individual blood pressure variability on the progression of atherosclerosis in carotid and coronary arteries: a post hoc analysis of the NORMALISE and PREVENT studies.
    Kim JS; Park S; Yan P; Jeffers BW; Cerezo C
    Eur Heart J Cardiovasc Pharmacother; 2017 Apr; 3(2):82-89. PubMed ID: 27533954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low Baseline High-Sensitive C-Reactive Protein is Associated with Coronary Atherosclerosis Regression: Insights from the MILLION Study.
    Sakata K; Gamou T; Tada H; Hayashi K; Ino H; Yamagishi M; ;
    J Atheroscler Thromb; 2019 May; 26(5):442-451. PubMed ID: 30249940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis.
    Sipahi I; Tuzcu EM; Schoenhagen P; Wolski KE; Nicholls SJ; Balog C; Crowe TD; Nissen SE
    J Am Coll Cardiol; 2006 Aug; 48(4):833-8. PubMed ID: 16904557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of combination therapy with amlodipine and atorvastatin on plasma adiponectin levels in hypertensive patients with coronary artery disease: combination therapy and adiponectin.
    Li M; Xu A; Lam KS; Cheung BM; Tse HF
    Postgrad Med; 2011 Nov; 123(6):66-71. PubMed ID: 22104455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease.
    Schieffer B; Bünte C; Witte J; Hoeper K; Böger RH; Schwedhelm E; Drexler H
    J Am Coll Cardiol; 2004 Jul; 44(2):362-8. PubMed ID: 15261932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study.
    Esnault VL; Brown EA; Apetrei E; Bagon J; Calvo C; DeChatel R; Holdaas H; Krcmery S; Kobalava Z;
    Clin Ther; 2008 Mar; 30(3):482-98. PubMed ID: 18405787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antihypertensive agents and cardiovascular events in patients with coronary disease and normal blood pressure.
    Aboyans V; Lacroix P; Cassat C
    JAMA; 2005 Mar; 293(10):1187; author reply 1188-9. PubMed ID: 15755937
    [No Abstract]   [Full Text] [Related]  

  • 12. Prospective, randomized, single-blind comparison of effects of 6 months of treatment with telmisartan versus enalapril on high-molecular-weight adiponectin concentrations in patients with coronary artery disease.
    Satoh M; Tabuchi T; Minami Y; Takahashi Y; Itoh T; Nakamura M
    Clin Ther; 2009 Oct; 31(10):2113-25. PubMed ID: 19922882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost analysis of amlodipine versus enalapril in patients with coronary artery disease and normal blood pressure: findings from the CAMELOT economic substudy.
    Menzin J; Boulanger L; Tang S; Thakker K; Nissen SE
    Appl Health Econ Health Policy; 2008; 6(2-3):157-62. PubMed ID: 19231908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Patients with coronary disease and normal blood pressure: amlodipine vs. enalapril -- regarding the contribution in DMW 4/2005].
    Traut V
    Dtsch Med Wochenschr; 2005 May; 130(20):1279; author reply 1279-80. PubMed ID: 15889333
    [No Abstract]   [Full Text] [Related]  

  • 15. Haemorheological disturbances in hypertensive type 2 diabetic patients--influence of antihypertensive therapy.
    Kearney-Schwartz A; Virion JM; Stoltz JF; Drouin P; Zannad F
    Fundam Clin Pharmacol; 2007 Aug; 21(4):387-96. PubMed ID: 17635177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of visit-to-visit blood pressure variability on cardiovascular events in patients with coronary artery disease and well-controlled blood pressure.
    Park S; Yan P; Cerezo C; Jeffers BW
    J Am Soc Hypertens; 2016 Oct; 10(10):799-810. PubMed ID: 27720066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease.
    Tayebjee MH; Lip GY; Tan KT; Patel JV; Hughes EA; MacFadyen RJ
    Am J Cardiol; 2005 Aug; 96(3):339-45. PubMed ID: 16054454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Hypertensive Patients With Diabetes and Microalbuminuria With Combination Indapamide SR/Amlodipine: Retrospective Analysis of NESTOR.
    Hanon O; Boully C; Caillard L; Labourée F; Cochiello S; Chaussade E
    Am J Hypertens; 2015 Aug; 28(8):1064-71. PubMed ID: 25628416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Rakugi H; Ogihara T; Miyata Y; Sasai K; Totsuka N
    Clin Ther; 2012 Apr; 34(4):838-48. PubMed ID: 22440192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesarten on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial.
    Hirohata A; Yamamoto K; Miyoshi T; Hatanaka K; Hirohata S; Yamawaki H; Komatsubara I; Murakami M; Hirose E; Sato S; Ohkawa K; Ishizawa M; Yamaji H; Kawamura H; Kusachi S; Murakami T; Hina K; Ohe T
    J Am Coll Cardiol; 2010 Mar; 55(10):976-82. PubMed ID: 20202514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.